U.S. CDC advisers back Moderna COVID vaccine for teens, older children
Reuters
Published Jun 23, 2022 11:36AM ET
Updated Jun 23, 2022 03:16PM ET
By Manas Mishra
(Reuters) -Advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Thursday unanimously voted to recommend use of Moderna (NASDAQ:MRNA) Inc's COVID-19 vaccine for children and adolescents aged 6 to 17.
CDC Director Rochelle Walensky is expected to sign off on the recommendations soon, which would allow the U.S. government to start rolling out the Moderna vaccine for these age groups.
That would mean both mRNA COVID vaccines would be available to all Americans ages 6-months-old and up.
The Pfizer-BioNTech vaccine, based on similar messenger RNA technology, has been available for teens for over a year and for children aged 5-11 since October.
Roughly 25 million U.S. children and adolescents in that age group have yet to receive even one dose of a COVID-19 vaccine, CDC official Sara Oliver told the expert advisory panel.
There have been concerns that the Moderna vaccine, which is given at a higher dose than the Pfizer/BioNTech shot, may cause types of heart inflammation at higher rates, primarily in younger males.
The agency last week said more recent U.S. data showed that while there was a numerically higher rate of myocarditis or pericarditis with Moderna's shot, the findings were not statistically significant, meaning they might be due to chance.
The FDA authorized Moderna's vaccine just last week for the 6-11 age group, along with clearance for use in children as young as 6 months to 5-years-old.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.